Every year, hospitals in the United States administer hundreds of millions of intravenous infusions. Each one carries a margin for error – a wrong concentration, a contaminated line, a misidentified bag – that can turn a routine therapy into a life-threatening event. As healthcare systems enter 2026, the pressure to modernize infusion therapy practices has never been greater. New clinical evidence, updated regulatory guidance, and smarter device technology are reshaping how clinicians approach IV solutions, vascular access, and patient monitoring. For professionals working at the intersection of patient safety and supply chain management, staying current with these shifts is not optional – it is essential.
For hospital buyers and clinical supply coordinators managing procurement across multiple product categories, distributors like Map Medical offer consolidated access to B Braun’s infusion portfolio alongside other leading brands, which simplifies vendor management without sacrificing product choice.
The Evolving Landscape Of Infusion Therapy In 2026
Infusion therapy remains one of the most common interventions in acute and chronic care settings. Estimates suggest that up to 90% of hospitalized patients receive some form of IV therapy during their stay. Despite its prevalence, infusion-related adverse events – including infiltration, phlebitis, catheter-associated bloodstream infections (CLABSI), and medication errors – continue to account for a significant share of preventable patient harm.
In 2026, three forces are reshaping how hospitals and outpatient infusion centers approach this challenge: technology integration, standardization of vascular access protocols, and a renewed focus on IV fluid stewardship.
Trend 1 – Smart Infusion Systems And Dose Error Reduction
The adoption of smart infusion pumps with drug libraries and dose error reduction software (DERS) has accelerated significantly over the past several years. In 2026, health systems are moving beyond basic DERS implementation toward full integration of infusion pump data with electronic health records (EHR) and pharmacy systems.
What this means in practice:
- Real-time alerts when programmed doses fall outside protocol limits
- Automatic documentation of infusion parameters in the patient chart
- Pharmacy-side visibility into what is currently infusing at the bedside
- Closed-loop medication administration that reduces manual transcription errors
The Joint Commission and the Institute for Safe Medication Practices (ISMP) have both issued updated guidance encouraging health systems to audit their drug library compliance rates and address alert fatigue – a known risk when DERS systems generate too many low-priority warnings.
Trend 2 – Iv Fluid Stewardship And Balanced Crystalloid Use
For years, normal saline (0.9% sodium chloride) was the default IV fluid for most clinical indications. A growing body of evidence – including landmark trials such as SMART and SALT-ED – has challenged this assumption, demonstrating that balanced crystalloids like lactated Ringer’s solution may be associated with better outcomes in critically ill patients, particularly those with sepsis or acute kidney injury.
In 2026, formal IV fluid stewardship programs are being implemented in a growing number of ICUs and emergency departments. These programs mirror the structure of antimicrobial stewardship, designating clinical leads, establishing protocols for fluid selection, and tracking fluid balances as a quality metric.
| Fluid type | Sodium (mEq/L) | Chloride (mEq/L) | Common indication |
| Normal saline (0.9% NaCl) | 154 | 154 | Volume resuscitation, hyponatremia |
| Lactated Ringer’s | 130 | 109 | Surgical patients, trauma, sepsis |
| Plasmalyte | 140 | 98 | Burns, complex resuscitation |
| Dextrose 5% in water (D5W) | 0 | 0 | Free water replacement, drug dilution |
For clinicians and procurement teams seeking reliable sourcing of IV solutions, the range of B Braun IV fluids and infusion accessories covers the major crystalloid formulations used across these evolving protocols, including flexible bag formats that support modern workflow requirements.
Trend 3 – Advances In Vascular Access And Catheter Management
Vascular access – the process of establishing and maintaining a reliable entry point into the patient’s venous system – is a cornerstone of infusion therapy. In 2026, clinical practice is shifting toward a more deliberate, evidence-based approach to catheter selection, placement, and maintenance.
The rise of ultrasound-guided insertion
Ultrasound guidance for peripheral IV placement is no longer limited to difficult access patients in the emergency department. Many hospitals are expanding ultrasound use to all peripheral IV placements in inpatient settings, supported by training programs and portable ultrasound devices. This reduces failed first-attempt rates, patient discomfort, and catheter dwell-related complications.
Midline catheters as a bridge option
Midline catheters – inserted in the upper arm and terminating below the axilla – are gaining traction as a middle-ground option between short peripheral IVs and peripherally inserted central catheters (PICCs). They are appropriate for IV therapies lasting 1-4 weeks that do not require central venous access, offering longer dwell times and lower infection risk than standard peripheral catheters.
CLABSI prevention updates
Central line-associated bloodstream infections remain a significant patient safety target. The 2026 guidance from the CDC and professional bodies like the Infusion Nurses Society (INS) continues to emphasize maximal sterile barrier precautions, chlorhexidine-based skin antisepsis, and structured line maintenance bundles. Needleless connector disinfection – using standardized cap protocols and antiseptic barrier caps – has become a non-negotiable element of central line care in many institutions.
Trend 4 – Braun Products Shaping Modern Infusion Practice
B Braun is one of the most established names in infusion therapy, with a product portfolio that spans IV bags, infusion sets, needleless connectors, vascular access devices, and enteral nutrition systems. Several of their product lines are directly relevant to the 2026 trends outlined above.
B Braun IV bags and IV fluids
B Braun manufactures a broad range of IV solutions in their Excel and Ecoflac Plus container systems. These bags are produced under rigorous pharmaceutical-grade manufacturing standards and are available in multiple concentrations and volumes to support fluid stewardship initiatives. Their flexible bag design minimizes the need for venting and reduces particulate contamination risk during administration.
Discofix stopcocks
The B Braun Discofix is a widely used three-way stopcock designed for safe and reliable fluid management in IV lines. Its rotating disc mechanism reduces the risk of air entry, and its luer-lock connections provide secure attachment to infusion lines and syringes. In multi-drug infusion scenarios, stopcocks like the Discofix help clinicians manage complex line configurations without compromising sterility.
Ultrasite needleless connector
The Ultrasite by B Braun is a split-septum needleless connector designed to minimize blood reflux during connection and disconnection – a key factor in reducing catheter occlusions and infection risk. Its design allows both syringe and IV set attachment without a needle, supporting OSHA needlestick prevention requirements. The Ultrasite is compatible with standard luer-lock devices and has been validated for multiple access cycles.
| B Braun product | Category | Key benefit |
| Excel IV bag | IV solutions | Flexible container, reduced contamination risk |
| Discofix stopcock | Infusion accessories | Secure multi-line management |
| Ultrasite connector | Needleless access | Blood reflux reduction, infection prevention |
| Introcan Safety IV catheter | Vascular access | Passive safety mechanism post-insertion |
| Perfusor pump systems | Smart infusion | Dose error reduction, EHR integration |
Trend 5 – Outpatient And Home Infusion Expansion
The site of care for infusion therapy is continuing to shift. Driven by patient preference, payer incentives, and post-pandemic healthcare restructuring, outpatient infusion centers and home infusion services are absorbing a larger share of therapies that were once delivered exclusively in the hospital setting. These include IV antibiotics, biologics, immunoglobulins, and hydration therapy.
This shift creates new safety considerations. Clinicians and patients operating outside the hospital must have access to:
- Pre-mixed, ready-to-administer IV solutions that minimize compounding errors at home
- Infusion pumps designed for ambulatory use with sufficient battery life and user-friendly interfaces
- Clear patient education materials on catheter care, infusion schedules, and when to seek emergency care
- Reliable supply chains that ensure product availability without interruption
Healthcare systems building out home infusion programs must pay particular attention to product selection, since the safety net of bedside nursing is absent when a patient administers their own IV therapy.
Key Considerations For Infusion Therapy Safety In 2026
Healthcare organizations looking to strengthen their infusion therapy programs should consider the following priorities as they plan for the year ahead:
- Audit smart pump drug library compliance rates and address alert fatigue systematically
- Implement a formal IV fluid stewardship protocol with designated clinical leadership
- Expand ultrasound-guided vascular access training beyond the ED to inpatient units
- Standardize needleless connector disinfection practices across all central and peripheral lines
- Review home infusion supply and education protocols as outpatient volumes grow
- Evaluate product portfolios for compatibility with automation and EHR integration initiatives
FAQ: infusion therapy and patient safety
Q: What is the most common cause of infusion-related patient harm? Medication errors remain the leading category, including wrong dose, wrong drug, and wrong rate. However, catheter-related complications – particularly CLABSI and infiltration – contribute substantially to infusion-related morbidity. Pre-analytical and pre-administration errors (such as incorrect drug preparation or mislabeled bags) account for a significant portion of preventable events.
Q: What is the difference between B Braun IV bags and standard glass bottle IV systems? B Braun’s flexible IV bag systems, such as the Excel container, eliminate the need for air venting during infusion because the bag collapses as fluid is administered. This closed system reduces particulate contamination and microbial ingress compared to glass bottle systems, which require air entry to maintain flow. Flexible bags are now the dominant format in U.S. hospital formularies.
Q: How does the Discofix stopcock differ from standard stopcocks? The Discofix uses a rotating disc mechanism rather than a conventional rotating barrel design. This provides more precise directional control, reduces the risk of inadvertent port opening, and maintains a lower dead-space volume – which matters in pediatric and high-precision infusion scenarios where minimizing residual drug volume is clinically important.
Q: What are the INS guidelines for peripheral IV catheter dwell time in 2026? The Infusion Nurses Society moved away from routine 72-96 hour catheter rotation policies several years ago in favor of clinically indicated replacement – meaning catheters are replaced when there are signs of complications (phlebitis, infiltration, occlusion) rather than on a fixed schedule. However, institutional policies vary, and clinicians should follow their facility’s validated protocol alongside current INS Standards of Practice.
Q: Is home infusion therapy safe for complex antibiotics like vancomycin? Home infusion of vancomycin is well established and clinically appropriate for many stable patients when supported by a comprehensive monitoring program. This typically includes baseline and periodic renal function testing, therapeutic drug monitoring (trough or AUC-based), and access to a 24-hour clinical support line. Patient selection, education, and supply chain reliability are the most critical variables for safe home vancomycin therapy.
About the Author
